DE69330464T2 - Gruppe b streptococcus typ ii und typ v polysaccharid-protein konjugate als impfstoffe - Google Patents

Gruppe b streptococcus typ ii und typ v polysaccharid-protein konjugate als impfstoffe

Info

Publication number
DE69330464T2
DE69330464T2 DE69330464T DE69330464T DE69330464T2 DE 69330464 T2 DE69330464 T2 DE 69330464T2 DE 69330464 T DE69330464 T DE 69330464T DE 69330464 T DE69330464 T DE 69330464T DE 69330464 T2 DE69330464 T2 DE 69330464T2
Authority
DE
Germany
Prior art keywords
type
cps
streptococcus
polysaccharid
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69330464T
Other languages
English (en)
Other versions
DE69330464D1 (en
Inventor
Harold J Jennings
Dennis L Kasper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Council of Canada
Brigham and Womens Hospital Inc
Original Assignee
National Research Council of Canada
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26823688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69330464(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by National Research Council of Canada, Brigham and Womens Hospital Inc filed Critical National Research Council of Canada
Priority claimed from PCT/US1993/009056 external-priority patent/WO1994006467A1/en
Publication of DE69330464D1 publication Critical patent/DE69330464D1/de
Application granted granted Critical
Publication of DE69330464T2 publication Critical patent/DE69330464T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/813—Carrier is a saccharide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria
DE69330464T 1992-09-24 1993-09-24 Gruppe b streptococcus typ ii und typ v polysaccharid-protein konjugate als impfstoffe Expired - Fee Related DE69330464T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94997092A 1992-09-24 1992-09-24
US12555693A 1993-09-23 1993-09-23
PCT/US1993/009056 WO1994006467A1 (en) 1992-09-24 1993-09-24 Group b streptococcus type ii and type v polysaccharide-protein conjugate vaccines

Publications (2)

Publication Number Publication Date
DE69330464D1 DE69330464D1 (en) 2001-08-23
DE69330464T2 true DE69330464T2 (de) 2001-11-08

Family

ID=26823688

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69330464T Expired - Fee Related DE69330464T2 (de) 1992-09-24 1993-09-24 Gruppe b streptococcus typ ii und typ v polysaccharid-protein konjugate als impfstoffe

Country Status (16)

Country Link
US (2) US5795580A (de)
EP (1) EP0667787B1 (de)
JP (3) JP4163251B2 (de)
KR (1) KR100293017B1 (de)
AT (1) ATE203167T1 (de)
AU (1) AU690525B2 (de)
CA (1) CA2145397C (de)
DE (1) DE69330464T2 (de)
DK (1) DK0667787T3 (de)
ES (1) ES2160601T3 (de)
FI (1) FI110993B (de)
GR (1) GR3036928T3 (de)
IL (1) IL107103A (de)
NO (2) NO319569B1 (de)
NZ (2) NZ248766A (de)
PT (1) PT667787E (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0843372B1 (de) * 1996-11-18 2003-03-12 Japan Storage Battery Company Limited Positivelektrode für Lithiumbatterie und Lithiumbatterie
US6284250B1 (en) * 1998-02-05 2001-09-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Simplified method for removing free protein during preparation of protein-polysaccharide conjugates and vaccines using restricted-access media
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
ES2286133T3 (es) 2000-08-08 2007-12-01 St. Jude Children's Research Hospital Acidos nucleicos de polipeptidos de estreptococos del grupo b y composiciones terapeuticas y vacunas de los mismos.
SV2003000753A (es) * 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
US20030185858A1 (en) * 2001-08-15 2003-10-02 Birkett Ashley J. Immunogenic HBc chimer particles stabilized with an N-terminal cysteine
WO2003015815A1 (en) * 2001-08-21 2003-02-27 The Brigham And Women's Hospital, Inc. Improved conjugate vaccines
AU2003257003A1 (en) * 2002-07-30 2004-02-16 Baxter Healthcare S.A. Chimeric multivalent polysaccharide conjugate vaccines
JP2006522135A (ja) * 2003-03-31 2006-09-28 ザ ブライアム アンド ウィミンズ ホスピタル インコーポレーテッド 喘息およびアレルギーの処置のための両性イオン免疫調節剤
WO2005000346A1 (en) * 2003-06-23 2005-01-06 Baxter International Inc. Carrier proteins for vaccines
CA2586058A1 (en) 2004-11-01 2006-05-11 Dennis L. Kasper Modified streptococcal polysaccharides and uses thereof
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
US8206726B2 (en) * 2006-02-06 2012-06-26 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
GB201101665D0 (en) * 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
EP2731617A4 (de) 2011-07-12 2015-07-01 Brigham & Womens Hospital Lipidhaltige psa-zusammensetzungen, verfahren zu ihrer isolierung und verwendungsverfahren dafür
JP6266631B2 (ja) 2012-10-03 2018-01-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
RU2692923C2 (ru) * 2015-05-04 2019-06-28 Пфайзер Инк. Конъюгаты полисахарида стрептококка группы В и белка, способы получения конъюгатов, иммуногенные композиции, содержащие конъюгаты, и их применения
EP3337321A4 (de) 2015-08-19 2019-07-17 President and Fellows of Harvard College Lipidierte psa-zusammensetzungen und verfahren
CA3030974A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
US20220211859A1 (en) * 2019-05-10 2022-07-07 Glaxosmithkline Biologicals Sa Conjugate production

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4207414A (en) * 1978-08-16 1980-06-10 President And Fellows Of Harvard College Polysaccharide antigens
US4324887A (en) * 1978-08-16 1982-04-13 President And Fellows Of Harvard College Type II group B Streptococci polysaccharide
PT72812B (en) * 1980-04-14 1983-02-16 Merck & Co Inc Process for preparing group b streptococcal capsular polysccha-rides
US4438261A (en) * 1980-05-19 1984-03-20 Riker Laboratories, Inc. Anticoagulant substance
US4367222A (en) * 1980-06-09 1983-01-04 President And Fellows Of Harvard College Immune globulin specific to Group B streptococci
US4367223A (en) * 1980-06-09 1983-01-04 President And Fellows Of Harvard College Vaccine against Group B streptococci
US4356263A (en) * 1980-06-09 1982-10-26 President And Fellows Of Harvard College Method of making a polysaccharide vaccine
US4367221A (en) * 1980-06-09 1983-01-04 President And Fellows Of Harvard College Immunization against Group B streptococci
US4284537A (en) * 1980-07-03 1981-08-18 The United States Of America As Represented By The Department Of Health And Human Services Conjugate of streptococcal M protein peptide vaccine
US4425330A (en) * 1981-05-20 1984-01-10 Cornell Research Foundation, Inc. Bovine mastitis vaccine and method for detecting efficacy thereof
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4757134A (en) * 1982-12-02 1988-07-12 The Rockefeller University IgA binding protein
EP0175261B1 (de) * 1984-09-12 1991-12-11 Chiron Corporation Hybridpartikel-Immunogene
FR2581877B1 (fr) * 1985-05-14 1987-12-18 Louvain Universite Catholique Conjugue constitue d'une adhesine de paroi de s. mutans, de nature proteique et d'un polysaccharide de s. mutans, sa preparation et son utilisation notamment dans des vaccins anti-caries
US5302386A (en) * 1986-04-16 1994-04-12 Brigham And Women's Hospital, Inc. Bacterial antigens, antibodies, vaccines and methods of manufacture
ATE107703T1 (de) * 1986-04-16 1994-07-15 Brigham & Womens Hospital Bakterielle antigene, antikörper, impfstoffe und deren herstellung.
EP0419462A4 (en) * 1987-07-17 1991-07-17 Xoma Corporation Improved immunotoxin therapies utilizing purified ricin a-chain species
IL95578A (en) * 1989-09-15 1998-08-16 Gen Hospital Corp A vaccine made from polysaccharide and protein
DE69019164T2 (de) * 1989-12-14 1995-09-07 Ca Nat Research Council Verbessertes meningokokkale polysaccharidkonjugatvakzin.
FR2682388B1 (fr) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.

Also Published As

Publication number Publication date
US5993825A (en) 1999-11-30
EP0667787B1 (de) 2001-07-18
FI110993B (fi) 2003-05-15
NO951152D0 (no) 1995-03-24
JP2005306884A (ja) 2005-11-04
JP2009132727A (ja) 2009-06-18
IL107103A (en) 2001-03-19
NO951109L (no) 1995-05-22
CA2145397C (en) 2007-10-30
NO951109D0 (no) 1995-03-23
JP4308174B2 (ja) 2009-08-05
DK0667787T3 (da) 2001-10-29
NZ248766A (en) 1996-11-26
DE69330464D1 (en) 2001-08-23
JP4163251B2 (ja) 2008-10-08
FI951412A (fi) 1995-05-24
KR950703361A (ko) 1995-09-20
ATE203167T1 (de) 2001-08-15
AU690525B2 (en) 1998-04-30
IL107103A0 (en) 1994-08-26
PT667787E (pt) 2001-10-31
NO319569B1 (no) 2005-08-29
ES2160601T3 (es) 2001-11-16
AU5137893A (en) 1994-04-12
KR100293017B1 (ko) 2001-09-17
US5795580A (en) 1998-08-18
JPH08501563A (ja) 1996-02-20
NZ299249A (en) 2000-08-25
EP0667787A1 (de) 1995-08-23
FI951412A0 (fi) 1995-03-24
CA2145397A1 (en) 1994-03-31
GR3036928T3 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
DE69330464T2 (de) Gruppe b streptococcus typ ii und typ v polysaccharid-protein konjugate als impfstoffe
ES8704350A1 (es) Procedimiento para la preparacion de un conjugado bacteriano
CA1276109C (en) Immunogenic conjugates
US6177085B1 (en) Generation of immune response using immunogenic conjugate of molecules
US5425946A (en) Vaccines against group C Neisseria meningitidis
AU634154B2 (en) Decoupled fiber optic feedthrough assembly
CA1340956C (en) Synthetic peptides representing a t-cell epitope as a carrier molecule for conjugate vaccines
NO913518L (no) Vaksiner for ikke typebestembar haemophilus influenzae.
LU91609I2 (fr) Sérotype pneumococcique polysaccharidique 1,4,5,6B,7F,9V,14 et 23F conjugé aux protéines D (dérivé du non-typable Haemophilus influenzae); Sérotype pneumococcique polysaccaridique 18C conjugé au transporteur anatoxine tétanique protéines; Sérotype pneumococcique polysaccharidique 19F conjugé au transporteur anatoxine diphtérique protéines (SYNFLORIX - Vaccin pneumococcique polysaccharidique conjugé (adsorbé)
US5192540A (en) Haemophilus influenzae type b oxidized polysaccharide-outer membrane protein conjugate vaccine
IE840197L (en) Polysaccharide protein conjugate vaccine
CA2171942A1 (en) Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
PT81338A (en) Antigens particularly envelope antigens of the virus of lymphadenopathies and of the acquired immuno-depressive syndrome and virus process for producing virus envelope antigens in the preparation of immunogenic compositions or for the diagnosis of the presence of antibodies against this virus
DK0754055T3 (da) Gruppe A-streptokok-polysaccharid-immunogen-præparater og metoder
CA2277141A1 (en) Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this procedure
EP0338265B1 (de) Haemophilus influenzae Typ B Polysaccharid-Aussermembranprotein-Konjugat als Impfstoff
UA27754C2 (uk) Комбінована педіатрична вакцина, спосіб одночасної комбінованої вакцинації
WO1993014206A3 (en) Synthetic peptides for a rubella vaccine
KR910011897A (ko) 말라리아 백신
CA1251396A (en) Vaccines comprising immunogenic protein or peptide complexes
Lüscher et al. Induction of immunological tolerance to the penicilloyl antigenic determinant—iv. The effect of BPO-oligolysines and cholestanol-bearing BPO-oligolysines on murine IgE responses
IT1237196B (it) Peptidi sintetici e loro uso come carriers universali per la preparazione di coniugati immunogenici adatti per lo sviluppo di vaccini sintetici
TH5452EX (th) วัคซีนสังเคราะห์เพื่อต่อต้านฟันผุ
SA96170157B1 (ar) تركيب لقاح composition vaccine يشتمل على مولد مضاد متعدد سكريد مقترن antigen conjugated polsaccharide يتم امتزازه على فوسفات الألومنيوم aluminum phosphate
HUP0002359A2 (hu) B-csoportú meningokokkusz porint és Haemophilus influenzae poliszacharidot tartalmazó immunogén konjugátumok

Legal Events

Date Code Title Description
8363 Opposition against the patent
8339 Ceased/non-payment of the annual fee